Navigation Links
Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
Date:2/5/2010

laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomic Services is a CRO for pharmacogenomic, translational research and clinical trials.

Cautionary Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release.

SOURCE Transgenomic, Inc.

RELATED LINKS
http://www.transgenomic.com

'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
2. Transgenomic, Inc. Reports Third Quarter 2009 Results
3. Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease
4. Transgenomic, Inc. Reports Second Quarter 2009 Results
5. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
6. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic, Inc. Announces Appointment of New Board Members
8. Transgenomic, Inc. Reports First Quarter 2009 Results
9. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
10. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
11. Webcast Alert: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... UK, and BRUSSELS, Belgium (PRWEB) June 03, 2015 ... and beyond, photonics plays an important part in enabling ... the European Commission. Innovation and technology leaders helped bring ... in thematic sessions during the Photonics21 annual meeting ... was a sponsor of the event, held 28 and ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has ... by Product , Test, Application & End User - ... The bioburden testing market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... limit testing market is segmented into consumables and instruments. ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has announced the addition ... by Products - Global Forecast to 2020" report ... is expected to reach $17.0 Billion in 2020 from ... during the forecast period of 2015 to 2020 ... of a range of products for wide applications, decreasing ...
(Date:6/2/2015)... Pa. , June 2, 2015   BioClinica ... and technology provider, today announced that David Peters ... been named Executive Vice President and Chief Financial Officer ... 2015. Peters brings more than 25 years ... pharmaceutical services. "David has extensive and deep knowledge in ...
Breaking Biology Technology:Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2BioClinica Names David Peters New Chief Financial Officer 2
... NEW YORK, April 10 Intellect Neurosciences,Inc. (OTC ... obtained a,Notice of Allowance and completed the grant ... Company,s ANTISENILIN(R) antibodies and,products being developed by the ... the European patent is expected in several weeks. ...
... Va., April 10 Insmed Inc. (Nasdaq:,INSM), a ... of a letter and questionnaire from the Chairman ... Subcommittee on Health,on the possible development of legislation ... Sent to approximately 30 stakeholders in the biotechnology ...
... Product Candidate -, PRINCETON, N.J., April 10, ... and protein production,company, today announced that it has ... Pharmaceuticals, LLC. According to the,agreement, Laureate will produce ... is planned for use in clinical trials, and ...
Cached Biology Technology:Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 2Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 3Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease 4Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 2Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 3Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... 8, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... members of the executive management team will present at the ... Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company Technology, ... ET Location: The New York Palace Hotel, New ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... (ACT) therapy is used to treat patients with metastatic solid ... cancer cells, and some of their immune T cells. When ... cells that stimulate the T cells to cause an immune ... re-infused into the patient to mount an immunological, anti-cancer response ...
... died in Britain of cancer of the liver. Eventually, researchers ... aflatoxin as the cause of this mysterious 'turkey X' disease. ... most virulent natural carcinogenic substances. , The tasteless toxin is ... arid regions, in the south-west of the US and in ...
... Rutgers University will lead a new $52.7 million research ... play in life's most fundamental processes and point the ... Rutgers Professor Gaetano Montelione, the Northeast Structural Genomics Consortium ... one of the largest in Rutgers' history, will reinforce ...
Cached Biology News:Corn grain mould used as pesticide 2Rutgers to lead $52.7 million protein research program 2Rutgers to lead $52.7 million protein research program 3Rutgers to lead $52.7 million protein research program 4
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
Biology Products: